Grants for For Profit Organizations Other Than Small Businesses

The "2024 Workplace Safety Grants for Health Care Entities" program is designed to enhance safety in healthcare environments through grants supporting projects focused on training staff in de-escalation and positive support services and increasing safety measures. Authorized by 2023 Session Law, Chapter 70, Article 4, Section 109, it aims for long-term improvements in safety and stability for both staff and patients. The program will distribute funds competitively, with anticipated multiple funding cycles depending on fund availability. The total program funding allocated is $4,400,000, with this cycle's estimated amount at $1,500,000 aimed to support around 30 awards.

The MBRP TTDA is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical application in resource-limited settings, particularly within the pre-hospital, or early, acute phase of care environments. Applications must address one or more of the critical gaps included in the FY24 MBRP TTDA Focus Areas. Products under development must address the needs of military Service Members, Veterans, their beneficiaries, and the American public.The product(s) to be developed may be a tangible item such as a medical device or pharmacologic agent (including, but not limited to, drugs or biologics). Knowledge products may be considered, provided that the knowledge is applicable to a technology or therapeutic under development. (A knowledge product is a non-materiel product that addresses an identified need in one or more of the FY24 MBRP TTDA Focus Areas. A knowledge product is based on current evidence, aims to transition clinical practice standards, training, or tools into clinical practice, or supports materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)At the time of pre-application submission the proposed product must have achieved a minimum technology readiness level (TRL) or knowledge readiness level (KRL) of 3 (Appendix II).Proof-of-concept AND a prototype/preliminary version of the proposed product demonstrating its potential utility must be established at the time of pre-application submission. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.This award mechanism is intended to facilitate progression of research that is supported by significant preliminary data but has not yet advanced to the level of clinical use. Examples of the types of research that may be supported include, but are not limited to: Testing new therapeutic or technologic modalities (e.g., agents, delivery systems, chemical modification of lead compounds, device testing and/or validation) using established or validated preclinical systems Designing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or technologies for use in advanced preclinical studies Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity studies Investigational New Drug- or Investigational Device Exemption-enabling studiesClinical trials and clinical research studies ARE NOT PERMITTED under this award mechanism. Projects involving limited use of commercially available human cells or anatomical specimens are permitted, provided that the use of such specimens is necessary for device or product development. Applicants interested in proposing clinical research should consider submitting to the FY24 MBRP Patient-Centered Research Award mechanism (HT942524MBRPPCRA).A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Impact: The overall impact of the proposed research is a key component of this award mechanism. High-impact research will, if successful, lead to the development and translation of therapeutic or technologic advances for clinical application in the care of burn-injured casualties, such as detection, diagnosis, treatment, or burn complication prevention.Relevance to Military Health: Relevance to the health care needs of burn-injured military Service Members is a key feature of this award.Use of DOD or Department of Veterans Affairs (VA) Resources: Applications involving multidisciplinary collaborations among academia, industry, the military Services, the VA, and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix IV.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.The CDMRP expects to allot approximately $4.4M to fund approximately two MBRP Technology/Therapeutic Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.The funding instrument for awards made under the program announcement will be assistance agreements, contracts, or Other Transactions. The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement. The USAMRDC will also consider the use of Other Transactions (OTs) as a vehicle for award, in accordance with the conditions in 10 USC 4021 and 10 USC 4022.An assistance agreement can take the form of a grant or cooperative agreement. The level of government involvement during the projects period of performance is the key factor in determining whether to award a grant or cooperative agreement. If no substantial government involvement is anticipated, a grant will be made (31 USC 6304). Conversely, if substantial government involvement is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that members of the U.S. government will assist, guide, coordinate, or participate in project activities.A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government.An Other Transaction will also be considered as a vehicle for award under this BAA, in accordance with 10 USC 4021 and 10 USC 4022. The OT authorities were created to give DOD the flexibility necessary to adopt and incorporate business practices that reflect commercial industry standards and best practices into its award instruments. When leveraged appropriately, OTs provide the government with access to state-of-the-art technology solutions from traditional and non-traditional defense contractors (NDCs), through a multitude of potential teaming arrangements tailored to the particular project and the needs of the participants. OTs can help to foster new relationships and practices involving traditional and NDCs, especially those that may not be interested in entering into FAR-based contracts with the government; broaden the industrial base available to government; support dual-use projects; encourage flexible, quicker, and cheaper project design and execution; leverage commercial industry investment in technology development and partner with industry to ensure DOD requirements are incorporated into future technologies and products; and collaborate in innovative arrangements. OTs are not FAR-based procurement contracts, grants, cooperative agreements, or cooperative research and development agreements.The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY24 MBRP Technology/Therapeutic Development Award should not exceed $2.2M. Refer to Section II.D.6, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025. For additional information refer to Section II.F.1, Federal Award Notices.

This grant option, part of the Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program, aims to support early-stage research into innovative treatments and rehabilitative techniques for spinal cord and traumatic brain injuries. The Tier 1 Pilot Project Grant does not require preliminary data but encourages it, reflecting early investment as researchers prepare to seek larger grants. The funding amount can reach up to $125,000 for a project duration of two years with an additional one-year no-cost extension.

The MMRDA mechanism is intended to fund the logical continuation of previously DOD-funded research or development efforts relevant to the above FY24 JWMRP Focus Areas with the highest potential to augment and accelerate medical product development and health care solutions for active-duty Service Members, their Families, Veterans, and/or the American public. Collaboration with DOD organizations is encouraged when this alliance would contribute to the success of the research effort, and any funds designated for DOD laboratories or activities should be identified in the application/proposal through submission of a Suggested Intragovernmental/Intramural Budget Form, Attachment 15. Applications/proposals from small businesses and/or partnerships with industry are also encouraged. The MMRDA mechanism supports a wide range of research projects, spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, and translational research. A Clinical Research or Clinical Trial Option is available to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices, and technologies. Note: Applications/proposals submitted under this option will be required to submit additional relevant application/proposal materials.

This grant provides funding for researchers, especially early-career scientists and students, to develop and test new technologies for studying solar and space physics through low-cost suborbital flights.

Funding available through this RFA supports the ongoing research and development of diagnostic tests and devices to treat, detect, diagnose, monitor, and assist in the treatment of cancer. Relevant areas include: Devices and assays for cancer detection, diagnosis, prognosis, monitoring, treatment and prediction of response or resistance to treatment Markers for cancer prevention and control, companion diagnostic to a therapy Development of diagnostic tests to distinguish high-risk early lesions Generally, at the time that an applicant applies to CPRIT pursuant to this RFA, the company has developed a commercial prototype of the device or a pictorial representation of the functional components/elements of the device. With respect to diagnostics, the company has developed assays that work on human samples and whose importance is well justified for development into clinical assays. The applicant should be working toward submitting an Investigational Device Exemption (IDE) or a 510(k) or Premarketing Approval (PMA) and is typically within one year from filing an IDE (or later stage work.) Potential applicants that are not at or near this stage of product development should consider applying for a Texas Seed Company Award. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for organizations interested in submitting applications for projects that increase protections against gender-based violence for marginalized communities in Kosovo. Gender-based violence (GBV) is a global issue that affects one in three women in their lifetime. According to the 2022 U.S. Department of State’s Human Rights Report for Kosovo, a significant human rights issue in Kosovo included the lack of investigation of and accountability for GBV, including domestic or intimate partner violence, sexual violence, and other forms of such violence. Another issue of concern was crimes involving violence or threats of violence targeting ethnic minorities or other marginalized communities. There are also critical gaps in the systematic documentation and monitoring of the prevalence of GBV in the country. Furthermore, GBV survivors often lack awareness of their rights and access to support services. There are also social stigmas in reporting GBV coupled with cultural norms that try to keep partners together. To respond to these challenges, DRL is seeking proposals that work towards the Bureau’s goal of providing access to justice for individuals experiencing GBV, abuse, and exploitation in 2 Kosovo. The program should take an intersectional approach by considering particular issues facing LGBTQI+ women, women with disabilities, low-income women, women in public-facing positions, women from racial, religious, and ethnic minority communities, and other intersections are differently impacted by GBV. The program objectives are: 1) increasing public awareness of the various forms of GBV (i.e. psychological, physical, emotional, economic, etc.) as well as relevant laws and available protections; 2) strengthening collaboration among diverse stakeholders in all communities on rights-based, trauma-informed, and survivor-centered approaches to prevent and address GBV; and 3) providing survivor-centered support, including the provision of direct service assistance. Program activities may include but are not limited to: • Developing and implementing targeted awareness campaigns and community engagement initiatives regarding the different forms of GBV and available protections under current laws; • Strengthening the financial, technical and/or organizational capacity of local organizations in providing effective and survivor-centered support services, including, but not limited to, legal, psycho-social, and/or medical assistance; • Enhancing coordination among relevant stakeholders, including law enforcement, healthcare providers, and social services to improve GBV response mechanisms, including training direct service providers on how to engage with survivors; and • Conducting research and assessments to better understand the prevalence and dynamics of GBV in the country and inform evidence-based interventions.

Funding available through this RFA supports company formation, as well as early research and development of novel oncology therapeutics, devices, treatment-oriented information technology products, diagnostics, or tools. The objective of the SEED Award program is to start with an interesting technology and to progress it toward a commercially viable business opportunity, i.e., make it more attractive to private funding agents. Typically, applicants have completed the following activities: Identified a novel therapeutic, diagnostic technology, or clinical tool and shown a biological effect Conducted preliminary safety and toxicology testing (in the case of therapeutic agents) Shown the product can be manufactured at small scale or as a prototype Assessed the business opportunity and organized a business plan that begins to address key issues (clinical utility, target market, financial plan, IP strategy, technical challenges, etc.) and lays out a preliminary development plan (formulation, toxicology, scale up, IND-enabling studies, phase 1 clinical trials, regulatory pathway, etc.). Established a company

Funding available through this RFA supports the ongoing research and development of innovative products, services, and infrastructure with significant potential impact on patient care. Generally, at this stage, the company has identified and characterized a lead compound; demonstrated efficacy in multiple translationally relevant animal models; completed pilot/dose ranging toxicology studies; determined the feasibility of a scalable, GMP compliant manufacturing process, including release assays; and identified a prototype formulation suitable for further development. The applicant is typically within one year from filing an IND/IDE or already in Phase 1. With appropriate justification, companies may use CPRIT funds to support the following: Studies that establish preclinical proof of concept (safety and efficacy) CMC/manufacturing development GLP safety studies to support INDs Phase 1 in humans to establish safety and a recommended dose for phase 2 Phase 2 studies to determine safety and efficacy in initial targeted patient population

The City of Stamford administers the Community Microgrant Program to support neighborhood level projects that improve quality of life across Stamford. The program provides small grants for sustainable and innovative initiatives identified by residents and community groups. Projects that create long term community benefit, invest in physical spaces and tools, and pilot new ideas are prioritized. The program has 75,000 dollars available for 2024, and grants may range from 1,000 to 10,000 dollars. Funds may support a wide range of activities based on local needs as identified by applicants. Eligible applicants include Stamford based nonprofit and charitable organizations as well as resident groups without legal nonprofit status that secure a fiscal agent such as a local 501(c)(3) organization or a city department. For profit organizations and individuals are not eligible. Projects must serve Stamford neighborhoods and residents. Applications are due May 3, 2024. Grant duration is not specified. Additional information is available from the City of Stamford.

The Mayor’s Office of Cultural Economy is offering a 2024 Grant Funding Program designed to support and promote the cultural economy of New Orleans. This program aligns with the office's mission to foster economic growth through cultural activities. For the FY24 cycle, twenty-five grants of $2,000 each will be awarded. The grants target individuals and organizations that are actively engaged in promoting the cultural economy. This includes educating youth, training cultural producers, providing networking opportunities, and creating cultural events. Eligible applicants include State and federal 501(c)3 nonprofits, for-profit businesses licensed with the City and State (for community/cultural activities only), and individuals such as artists who have secured a fiscal agent. The program aims to strengthen the cultural sector by supporting initiatives that build capacity and generate economic activity. The program prioritizes workshops, training, and conferences that enhance the capacity of cultural non-profits, neighborhood organizations, and cultural businesses. This capacity building encompasses networking, skill development (such as fundraising and grant writing), programming improvement, education on sustainability, and learning new concepts like place-based planning. Additionally, the grants support workshops, training, and conferences within specific Cultural Economy segments including Entertainment, Design, Preservation, Culinary Arts, Literary Arts and Humanities, and Visual Arts and Crafts. Expected outcomes include the creation of cultural events, increased employment for cultural workers (e.g., musicians), and increased sales for art and cultural vendors, thereby attracting tourists. The program's theory of change is that by investing in cultural education, training, networking, and events, the Office of Cultural Economy can stimulate economic growth and enhance the vibrancy of New Orleans' cultural landscape. All funded programs, events, and activities are required to acknowledge support from the Office of Cultural Economy, ensuring visibility and accountability.

Funding available through this RFA supports the ongoing research and development of new and emerging technologies for the detection, diagnosis, prognosis, monitoring, or treatment of cancer. CPRIT created this RFA to fund new and emerging technology projects that do not easily fit into any of the three other CPRIT Product Development Research RFAs. Proposals may include, but are not limited to, bioinformatics, artificial intelligence, production of radionuclides or their precursors, manufacture of cell-based therapies, processes to improve the quality of the samples used for cancer research or clinical care, and biomanufacturing of therapeutics. With appropriate justification, companies may use CPRIT funds to support studies that establish preclinical proof of concept, product validation, design, production, manufacturing and development, and clinical studies demonstrating safety and efficacy.

To implement a project aimed at advancing U.S. foreign policy and national security priorities by supporting initiatives that ensure partner states strategic trade control systems meet international standards and by engaging on bilateral, regional and multilateral levels with foreign governments to aid in the establishment of independent capabilities to regulate transfers of weapons of mass destruction, WMD-related items, conventional arms, and related dual-use items, and to detect, interdict, investigate, and prosecute illicit transfers of such items.

The Fiscal Year (FY) 2024 Port Security Grant Program (PSGP) is one of four grant programs that constitute DHS/FEMAs focus on transportation infrastructure security activities. These grant programs are part of a comprehensive set of measures authorized by Congress and implemented by the Administration to help strengthen the nations critical infrastructure against risks associated with potential terrorist attacks. The PSGP provides funds to state, local, and private sector maritime partners to support increased port-wide risk management and protect critical surface transportation infrastructure from acts of terrorism, major disasters, and other emergencies. The PSGP supports critical national seaports/terminals to enhance port security through enhanced facility and operational security. PSGP allows for a broad range of projects to be funded as long as they are applicable to enhancing maritime security capabilities. The entire breadth of the POETE (planning, operational, equipment, training, and exercise) is allowable under PSGP. Typical types of projects include: Patrol vessels Communications equipment Surveillance equipment Cybersecurity enhancements Hiring NEW security personnel Plan development Maritime security training Maritime security exercises Projects that are not primarily dedicated to the enhancement of maritime security capabilities (i.e., citywide projects, or business related projects) are not eligible.Applicants can submit applications for this funding opportunity through FEMA Grants Outcomes (GO). Access the system at https://go.fema.gov/

Bipartisan Infrastructure Law (BIL) Joint Office of Energy and Transportation: Communities Taking Charge Accelerator, Fiscal Year 2024 Funding Opportunity AnnouncementThis Funding Opportunity Announcement aims to help everyone ride and drive electric, foster public and private relationships, build interdisciplinary teams, advance the American blueprint for transportation decarbonization, and promote managed charging. The Joint Office of Energy and Transportation (Joint Office), through the U.S. Department of Energy Office of Energy Efficiency and Renewable Energy (EERE), is issuing a Funding Opportunity Announcement (FOA) entitled “Bipartisan Infrastructure Law (BIL) – Joint Office of Energy and Transportation: Communities Taking Charge Accelerator, Fiscal Year 2024 Funding Opportunity Announcement”. Awards made under this FOA will be funded, in whole or in part, with funds appropriated by the Infrastructure Investment and Jobs Act1, more commonly known as the Bipartisan Infrastructure Law (BIL). The BIL is a once-in-a-generation investment in modernizing and upgrading American infrastructure to enhance U.S. competitiveness, driving the creation of good-paying union jobs, tackling the climate crisis, and securing environmental justice and economic opportunity for disadvantaged communities2. The BIL appropriates more than $62 billion to the Department of Energy (DOE)3 to invest in American manufacturing and workers; expand access to energy efficiency and clean energy; deliver reliable, clean, and affordable power to more Americans; and demonstrate and deploy the clean-energy technologies of tomorrow through clean energy demonstrations. DOE’s BIL investments will support efforts to build a clean and equitable energy economy that achieves a zero-carbon electricity system by 2035, and to put the United States on a path to achieve net-zero emissions economy-wide by no later than 20504 to benefit all Americans. The BIL includes a historic $7.5 billion dedicated investment to build out a national network of Electric Vehicle (EV) chargers. As part of this investment, the BIL includes $300 million to establish a Joint Office of Energy and Transportation to study, plan, coordinate, and implement issues of joint concern between the U.S. Department of Energy and the U.S. Department of Transportation (DOT). The Communities Taking Charge Accelerator FOA and related activities align with the Joint Office mission to provide a modernized and interagency approach to support the deployment of zeroemission, convenient, accessible, and equitable transportation infrastructure. The activities to be funded under this FOA support BIL section Title VIII, Division J, Federal Highway Administration - Highway Infrastructure Program.

To implement a project aimed at advancing U.S. foreign policy and national security priorities by supporting initiatives that make decision-making structures and processes in fragile, conflict, or crisis-affected contexts more reflective of and responsive to the needs and perspectives of partner states to ensure strategic trade control systems meet international standards and by engaging on bilateral, regional and multilateral levels with foreign governments to aid in the establishment of independent capabilities to regulate transfers of weapons of mass destruction, WMD-related items, conventional arms, and related dual-use items, and to detect, interdict, investigate, and prosecute illicit transfers of such items.

This program provides matching grants to Illinois-based organizations, including local governments, nonprofits, and businesses, to enhance their competitiveness for federal funding in projects that support economic development and clean energy initiatives.

In FY23, the OCRP established a new academy, the Ovarian Cancer Clinical Trial Academy (OCCTA), which will focus on clinical trial research in ovarian cancer. The intent of the OCCTA is to enhance knowledge within next generation of Early-Career Investigators (ECIs) in clinical trial research and to produce effective treatments and cures for ovarian cancer. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. The OCCTA strives to develop successful, highly productive ovarian cancer clinical trialists in a collaborative research and career development environment, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials.

The Fiscal Year (FY) 2024 Intercity Bus Security Grant Program (IBSGP) is one of four grant programs that constitute the Department of Homeland Security (DHS)/Federal Emergency Management Agencys (FEMA) focus on transportation infrastructure security activities. These grant programs are part of a comprehensive set of measures authorized by Congress and implemented by DHS to help strengthen the nations critical infrastructure against potential terrorist attacks. The IBSGP provides funds to intercity bus companies to protect critical surface transportation infrastructure and the travelling public from acts of terrorism. For FY 2024, DHS is focused on the criticality of information sharing and collaboration to building a national culture of preparedness and protecting against terrorism and other threats to our national security. DHS and its homeland security mission were born from the failures among federal agencies and between the federal agencies and state and local authorities to share critical information related to the threat of terrorism prior to the September 11, 2001, attacks. The threat profile has changed in the last two decades we now face continuous cyber threats by sophisticated actors, threats to soft targets and crowded places, threats to our democratic election process and threats from new and emerging technologies. That said, information sharing and cooperation between state, local, tribal, and territorial authorities, and federal agencies, including all DHS officials, is just as vital, and perhaps even more vital, today. Therefore, for FY 2024, we have identified two priority areas, related to some of the most serious threats that Amtrak should address with IPR funds. These two priorities areas include enhancing cybersecurity and enhancing the protection of soft targets/crowded places. DHS also will continue to forge partnerships to strengthen information sharing and collaboration in each of these priority areas. Applicants can submit applications for this funding opportunity through FEMA Grants Outcomes (GO). Access the system at https://go.fema.gov/.

This initiative provides funding opportunities for private sector entities in Jordan to collaborate with USAID in addressing key development challenges, focusing on economic growth, water security, governance, education, and the empowerment of women and youth.